^
Association details:
| Biomarker: | MAP2K1 K57T |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer
Excerpt:
We report the emergence of the novel MEK1V211D gatekeeper mutation in a patient with BRAFK601E colon cancer treated with the allosteric MEK inhibitor binimetinib and the anti-EGFR antibody panitumumab...The V211D mutation causes resistance to binimetinib by both increasing the catalytic activity of MEK1 and reducing its affinity for the drug.
DOI:
10.1158/2159-8290.CD-19-0356
